Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: Modifications of the oxazolidinone ring leading to the discovery of anacetrapib

Journal of Medicinal Chemistry

Volumn 54, Issue 13, 2011, Pages 4880-4895

  Smith, Cameron J ^a   Ali, Amjad ^a   Hammond, Milton L ^a   Li, Hong ^a   Lu, Zhijian ^a   Napolitano, Joann ^a   Taylor, Gayle E ^a   Thompson, Christopher F ^a   Anderson, Matt S ^a   Chen, Ying ^a   Eveland, Suzanne S ^a   Guo, Qiu ^a   Hyland, Sheryl A ^a   Milot, Denise P ^a   Sparrow, Carl P ^a   Wright, Samuel D ^a   Cumiskey, Anne Marie ^a   Latham, Melanie ^a   Peterson, Laurence B ^a   Rosa, Ray ^a   Pivnichny, James V ^a   Tong, Xinchun ^a   Xu, Suoyu S ^a   Sinclair, Peter J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[2' METHOXY 5' (PROPAN 2 YL) 4 (TRIFLUOROMETHYL)BIPHENYL 2 YL]METHYL] 4 METHYL 5 PHENYL 1,3 OXAZOLIDIN 2 ONE; 5 [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 3 [[2' METHOXY 5' (PROPAN 2 YL) 4 (TRIFLUOROMETHYL)BIPHENYL 2 YL]METHYL] 4 METHYL 1,3 OXAZOLIDIN 2 ONE; 5 [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 3 [[4' FLUORO 2' METHOXY 5' (PROPAN 2 YL) 4 (TRIFLUOROMETHYL)BIPHENYL 2 YL]METHYL] 4 METHYL 1,3 OXAZOLIDIN 2 ONE; 5 [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 3 [[4' FLUORO 2' METHOXY 5' (PROPAN 2 YL) 4 (TRIFLUOROMETHYL)BIPHENYL 2 YL]METHYL] 4,4 DIMETHYL 1,3 OXAZOLIDIN 2 ONE; 5 [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 3 [[4' FLUORO 2' METHOXY 5' (PROPAN 2 YL) 4 (TRIFLUOROMETHYL)BIPHENYL 2 YL]METHYL] 4,5 DIMETHYL 1,3 OXAZOLIDIN 2 ONE; 5 [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 4 ETHYL 3 [[2' METHOXY 5' (PROPAN 2 YL) 4 (TRIFLUOROMETHYL)BIPHENYL 2 YL]METHYL] 1,3 OXAZOLIDIN 2 ONE; ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXAZOLIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG STRUCTURE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSGENIC MOUSE;

ANIMALS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXAZOLIDINONES; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960165059     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200484c     Document Type: Article

References (58)

1. World Health Organization Cardiovascular Diseases-Fact Sheet no. 317. http://www.who.int/en/, February 28, 2007.
2. Kearney, P. M.; Blackwell, L.; Collins, R.; Keech, A.; Simes, J.; Peto, R.; Armitage, J.; Baigent, C. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 2008, 371, 117-125
3. Baigent, C.; Keech, A.; Kearney, P. M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, J. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins Lancet 2005, 366, 1267-1278
4. Rhoads, G.; Gulbrandsen, C.; Kagan, A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men N. Engl. J. Med. 1976, 294, 293-298
5. Castelli, W.; Doyle, J.; Gordon, T.; Hames, C.; Hjortland, M.; Hulley, S.; Kagan, A.; Zukel, W. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study Circulation 1977, 55, 767-772 (Pubitemid 8090093)
6. Gordon, T.; Castelli, W. P.; Hjortland, M. C.; Kannel, W. B.; Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study Am. J. Med. 1977, 62, 707-714 (Pubitemid 8110784)
7. Lewington, S.; Whitlock, G.; Clarke, R.; Sherliker, P.; Emberson, J.; Halsey, J.; Qizilbash, N.; Peto, R.; Collins, R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths Lancet 2008, 370, 1829-1839
8. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, J. Am. Med. Assoc. 1984, 251, 365-374.
9. Brown, B. G.; Stukovsky, K. H.; Zhao, X.-Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials Curr. Opin. Lipidol. 2006, 17, 631-636 (Pubitemid 44729955)
10. Otvos, J. D.; Collins, D.; Freedman, D. S.; Shalaurova, I.; Schaefer, E. J.; McNamara, J. R.; Bloomfield, H. E.; Robins, S. J. Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial Circulation 2006, 113, 1556-1563 (Pubitemid 43739414)
11. Pedersen, T. R.; Olsson, A. G.; Færgeman, O.; Kjekshus, J.; Wedel, H.; Berg, K.; Wilhelmsen, L.; Haghfelt, T.; Thorgeirsson, G.; Pyorala, K.; Miettinen, T.; Christophersen, B.; Tobert, J. A.; Musliner, T. A.; Cook, T. J. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S) Circulation 1998, 97, 1453-1460 (Pubitemid 28191300)
12. Singh, I. M.; Shishehbor, M. H.; Ansell, B. J. High-density lipoprotein as a therapeutic target: a systematic review J. Am. Med. Assoc. 2007, 298, 786-798 (Pubitemid 47263161)
13. Tall, A. R.; Yvan-Charvet, L.; Terasaka, N.; Pagler, T.; Wang, N. HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis Cell Metab. 2008, 7, 365-375 (Pubitemid 351598023)
14. Barkowski, R. S.; Frishman, W. H. HDL metabolism and CETP inhibition Cardiol. Rev. 2008, 16, 154-162 (Pubitemid 351549677)
15. Masson, D.; Jiang, X. C.; Lagrost, L.; Tall, A. R. The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis J. Lipid Res. 2009, 50 (Suppl S) S201-S206
16. Barter, P. J.; Brewer, H. B., Jr; Chapman, M. J.; Hennekens, C. H.; Rader, D. J.; Tall, A. R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler. Thromb. Vasc. Biol. 2003, 23, 160-167 (Pubitemid 36231923)
17. Brown, M. L.; Inazu, A.; Hesler, C. B.; Agellon, L. B.; Mann, C.; Whitlock, M. E.; Marcel, Y. L.; Milne, R. W.; Koizumi, J.; Mabuchi, H.; Takeda, R.; Tall, A. R. Molecular basis of lipid transfer protein deficiency in a family with increase high-density lipoproteins Nature 1989, 342, 448-451 (Pubitemid 19277523)
18. Inazu, A.; Brown, M. L.; Hesler, C. B.; Agellon, L. B.; Kolzumi, J.; Takata, K.; Maruhama, Y.; Mabuchi, H.; Tall, A. R. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N. Engl. J. Med. 1990, 323, 1234-1238 (Pubitemid 20366528)
19. Clark, R. W.; Sutfin, T. A.; Ruggeri, R. B.; Willauer, A. T.; Sugarman, E. D.; Magnus-Aryitey, G.; Cosgrove, P. G.; Sand, T. M.; Wester, R. T.; Williams, J. A.; Perlman, M. E.; Bamberger, M. J. Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib Arterioscler. Thromb. Vasc. Biol. 2004, 24, 490-497 (Pubitemid 38326143)
20. Brousseau, M. E.; Schaefer, E. J.; Wolfe, M. L.; Bloedon, L. T.; Digenio, A. G.; Clark, R. W.; Mancuso, J. P.; Rader, D. J. Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol N. Engl. J. Med. 2004, 350, 1505-1515 (Pubitemid 38477775)
21. Davidson, M. H.; McKenney, J. M.; Shear, C. L.; Revkin, J. H. Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals with Below-Average High-Density Lipoprotein Cholesterol Levels J. Am. Coll. Cardiol. 2006, 48, 1774-1781 (Pubitemid 44648633)
22. McKenney, J. M.; Davidson, M. H.; Shear, C. L.; Revkin, J. H. Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels on a Background of Atorvastatin J. Am. Coll. Cardiol. 2006, 48, 1782-1790 (Pubitemid 44648632)
23. de Grooth, G. J.; Kuivenhoven, J. A.; Stalenhoef, A. F. H.; de Graaf, J.; Zwinderman, A. H.; Posma, J. L.; van Tol, A.; Kastelein, J. J. P. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study Circulation 2002, 105, 2159-2165 (Pubitemid 34517159)
24. Kuivenhoven, J. A.; de Grooth, G. J.; Kawamura, H.; Klerkx, A. H.; Wilhelm, F.; Trip, M. D.; Kastelein, J. J. P. Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia Am. J. Cardiol. 2005, 95, 1085-1088 (Pubitemid 40544314)
25. Stein, E. A.; Stroes, E. S. G.; Steiner, G.; Buckley, B. M.; Capponi, A. M.; Burgess, T.; Niesor, E. J.; Kallend, D.; Kastelein, J. J. P. Safety and Tolerability of Dalcetrapib Am. J. Cardiol. 2009, 104, 82-91
26. Kastelein, J. J. P.; Duivenvoorden, R.; Deanfield, J.; de Groot, E.; Jukema, J. W.; Kaski, J.-C.; Munzel, T.; Taddei, S.; Lehnert, V.; Burgess, T.; Kallend, D.; Luscher, T. F. Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation Curr. Med. Res. Opin. 2011, 27, 141-150
27. Barter, P. J.; Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J. P.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.-C.; Waters, D. D.; Shear, C. L.; Revkin, J. H.; Buhr, K. A.; Fisher, M. R.; Tall, A. R.; Brewer, B. Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 2007, 357, 2109-2122 (Pubitemid 350146106)
28. Kastelein, J. J. P.; van, L. S. I.; Burgess, L.; Evans, G. W.; Kuivenhoven, J. A.; Barter, P. J.; Revkin, J. H.; Grobbee, D. E.; Riley, W. A.; Shear, C. L.; Duggan, W. T.; Bots, M. L. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N. Engl. J. Med. 2007, 356, 1620-1630 (Pubitemid 46631671)
29. Bots, M. L.; Visseren, F. L.; Evans, G. W.; Riley, W. A.; Revkin, J. H.; Tegeler, C. H.; Shear, C. L.; Duggan, W. T.; Vicari, R. M.; Grobbee, D. E.; Kastelein, J. J. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 2007, 370, 153-160 (Pubitemid 47042895)
30. Vergeer, M.; Bots, M. L.; van Leuven, S. I.; Basart, D. C.; Sijbrands, E. J.; Evans, G. W.; Grobbee, D. E.; Visseren, F. L.; Stalenhoef, A. F.; Stroes, E. S.; Kastelein, J. J. P. Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity Circulation 2008, 118, 2515-2522
31. Nissen, S. E.; Tardif, J.-C.; Nicholls, S. J.; Revkin, J. H.; Shear, C. L.; Duggan, W. T.; Ruzyllo, W.; Bachinsky, W. B.; Lasala, G. P.; Tuzcu, E. M. Effect of torcetrapib on the progression of coronary atherosclerosis N. Engl. J. Med. 2007, 356, 1304-1316 (Pubitemid 46513296)
32. Nicholls, S. J.; Tuzcu, E. M.; Brennan, D. M.; Tardif, J.-C.; Nissen, S. E. Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis Circulation 2008, 118, 2506-2514
33. Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A.-M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K. S.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S.-Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br. J. Pharmacol. 2008, 154, 1465-1473
34. Blasi, E.; Bamberger, M.; Knight, D.; Engwall, M.; Wolk, R.; Winter, S.; Betts, A.; John-Baptiste, A.; Keiser, J. Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure J. Cardiovasc. Pharmacol. 2009, 53, 507-516
35. DePasquale, M.; Cadelina, G.; Knight, D.; Loging, W.; Winter, S.; Blasi, E.; Perry, D.; Keiser, J. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors Drug Dev. Res. 2009, 70, 35-48
36. Hu, X.; Dietz, J. D.; Xia, C.; Knight, D. R.; Loging, W. T.; Smith, A. H.; Yuan, H.; Perry, D. A.; Keiser, J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 2009, 150, 2211-2219
37. Rader, D. J. Illuminating HDL-is it still a viable therapeutic target? N. Engl. J. Med. 2007, 357, 2180-2183 (Pubitemid 350146114)
38. Tall, A. R.; Yvan-Charvet, L.; Wang, N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 2007, 27, 257-260 (Pubitemid 46143036)
39. Tall, A. R. CETP inhibitors to increase HDL cholesterol levels N. Engl. J. Med. 2007, 356, 1364-1366 (Pubitemid 46513305)
40. Barter, P. J. Point: The Relationship between Cholesteryl Ester Transfer Protein and Cardiovascular Risk Clin. Chem. 2010, 56, 1547-1549
41. Sirtori, C. R.; Mombelli, G. Counterpoint: Cholesteryl Ester Transfer Protein Antagonism by Drugs-A Poor Choice Clin. Chem. 2010, 56, 1550-1553
42. Ranalletta, M.; Bierilo, K. K.; Chen, Y.; Milot, D.; Chen, Q.; Tung, E.; Houde, C.; Elowe, N. H.; Garcia-Calvo, M.; Porter, G.; Eveland, S.; Frantz-Wattley, B.; Kavana, M.; Addona, G.; Sinclair, P.; Sparrow, C.; O'Neill, E. A.; Koblan, K. S.; Sitlani, A.; Hubbard, B.; Fisher, T. S. Biochemical characterization of cholesteryl ester transfer protein inhibitors J. Lipid Res. 2010, 51, 2739-2752
43. Krishna, R.; Anderson, M. S.; Bergman, A. J.; Jin, B.; Fallon, M.; Cote, J.; Rosko, K.; Chavez-Eng, C.; Lutz, R.; Bloomfield, D. M.; Gutierrez, M.; Doherty, J.; Bieberdorf, F.; Chodakewitz, J.; Gottesdiener, K. M.; Wagner, J. A. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24 h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 2007, 370, 1907-1914 (Pubitemid 350192656)
44. Krishna, R.; Bergman, A, J.; Jin, B.; Fallon, M.; Cote, J.; Van Hoydonck, P.; Laethem, T.; Gendrano, I. N., III; Van Dyck, K.; Hilliard, D.; Laterza, O.; Snyder, K.; Chavez-Eng, C.; Lutz, R.; Chen, J.; Bloomfield, D. M.; De Smet, M.; Van Bortel, L. M.; Gutierrez, M.; Al-Huniti, N.; Dykstra, K.; Gottesdiener, K. M.; Wagner, J. A. Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects Clin. Pharmacol. Ther. 2008, 84, 679-683
45. Krishna, R.; Bergman, A. J.; Jin, B.; Garg, A.; Roadcap, B.; Chiou, R.; Dru, J.; Cote, J.; Laethem, T.; Wang, R. W.; Didolkar, V.; Vets, E.; Gottesdiener, K.; Wagner, J. A. Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers J. Clin. Pharmacol. 2009, 49, 80-87
46. Krishna, R.; Garg, A.; Panebianco, D.; Cote, J.; Bergman, A. J.; Van, H. P.; Laethem, T.; Van, D. K.; Chen, J.; Chavez-Eng, C.; Archer, L.; Lutz, R.; Hilliard, D.; Snyder, K.; Jin, B.; Van, B. L.; Lasseter, K. C.; Al-Huniti, N.; Dykstra, K.; Gottesdiener, K.; Wagner, J. A. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 2009, 68, 535-545
47. Krishna, R.; Garq, A.; Jin, B.; Keshavarz, S. S.; Bieberdorf, F. A.; Chodakewitz, J.; Wagner, J. A. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 2009, 67, 520-526
48. Bloomfield, D.; Carlson, G. L.; Sapre, A.; Tribble, D.; McKenney, J. M.; Littlejohn, T. W.; Sisk, C. M.; Mitchel, Y.; Pasternak, R. C. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am. Heart J. 2009, 157, 352-360
49. Yvan-Charvet, L.; Kling, J.; Pagler, T.; Li, H.; Hubbard, B.; Fisher, T.; Sparrow, C. P.; Taggart, A. K.; Tall, A. R. Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1430-1438
50. Cannon, C. P.; Dansky, H. M.; Davidson, M.; Gotto, A. M.; Brinton, E. A.; Gould, A. L.; Stepanavage, M.; Liu, S. X.; Shah, S.; Rubino, J.; Gibbons, P.; Hermanowski-Vosatka, A.; Binkowitz, B.; Mitchel, Y.; Barter, P. J. Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib Am. Heart J. 2009, 158, 513-519
51. Cannon, C. P.; Shah, S.; Dansky, H. M.; Davidson, M.; Brinton, E. A.; Gotto, A. M.; Stepanavage, M.; Liu, S. X.; Gibbons, P.; Ashraf, T. B.; Zafarino, J.; Mitchel, Y.; Barter, P. J. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease N. Engl. J. Med. 2010, 363, 2406-2415
52. Lu, Z.; Napolitano, J. B.; Theberge, A.; Ali, A.; Hammond, M. L.; Tan, E.; Tong, X.; Xu, S. S.; Latham, M. J.; Peterson, L. B.; Anderson, M. S.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Chen, Y.; Sparrow, C. P.; Wright, S. D.; Sinclair, P. J. Design of a novel class of biphenyl CETP inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 7469-7472
53. Thompson, C. F.; Ali, A.; Quraishi, N.; Lu, Z.; Hammond, M. L.; Sinclair, P. J.; Anderson, M. S.; Eveland, S. S.; Guo, Q.; Hyland, S. A.; Milot, D. P.; Sparrow, C. P.; Wright, S. D. Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein. ACS Med. Chem. Lett. 2011, 2, DOI: 10.1021/ml100309n.
54. Liu, J.; Ikemoto, N.; Petrillo, D.; Armstrong, J. D., III. Improved syntheses of α-BOC-aminoketones from α-BOC-amino-Weinreb amides using a pre-deprotonation protocol Tetrahedron Lett. 2002, 43, 8223-8226 (Pubitemid 35223342)
55. Fujita, M.; Hiyama, T. Erythro-directive reduction of alpha-substituted alkanones by means of hydrosilanes in acidic media J. Org. Chem. 1988, 53, 5415-5421
56. Eveland, S. S.; Milot, D. P.; Guo, Q.; Chen, Y.; Hyland, S. A.; Peterson, L. B.; Jezequel-Sur, S.; O'Donnell, G. T.; Zuck, P. D.; Ferrer, M.; Strulovici, B.; Wagner, J. A.; Tanaka, W. K.; Hilliard, D. A.; Laterza, O.; Wright, S. D.; Sparrow, C. P.; Anderson, M. S. A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology Anal. Biochem. 2007, 368, 239-249 (Pubitemid 47198567)
57. Tan, E. Y.; Hartmann, G.; Chen, Q.; Pereira, A.; Bradley, S.; Doss, G.; Zhang, A. S.; Ho, J. Z.; Braun, M. P.; Dean, D. C.; Tang, W.; Kumar, S. Pharmacokinetics, Metabolism, and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Rats and Rhesus Monkeys Drug Metab. Dispos. 2010, 38, 459-473
58. Marotti, K. R.; Castle, C. K.; Murray, R. W.; Rehberg, E. F.; Polites, H. G.; Melchior, G. W. The role of cholesteryl ester transfer protein in primate apolipoprotein A-I metabolism. Insights from studies with transgenic mice Arterioscler. Thromb. Vasc. Biol. 1992, 12, 736-744